SecBot SecBot
8-K ·Filed Aug 6, 2026

ZTS

Zoetis Inc.
BEARISH
Impact 7/10
Horizondays Processed3mo ago SEC0001555280-26-000038
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The significant guidance reduction, particularly the swing to negative organic operational growth, signals a worsening demand environment in the core U.S. companion animal business. Traders should expect a negative reaction and watch for further competitive pressure on key franchises like dermatology and parasiticides, as well as potential for additional cost-cutting measures.

DirectionBearish
Confidencehigh
Horizondays

Drugs in focus

ZTS drug pipeline →

Convenia

▼ Bearish Named in this 8-K
Impact
Phase
Approved
Time to market
Already on market since 2008
Next catalyst
None dated

What to watchConvenia is a mature, approved product facing generic erosion, a known headwind already priced into ZTS's ~50% decline from its 52-week high. The next meaningful catalyst for ZTS is its quarterly earnings (next likely in late October/November 2026), where Convenia generic impact will be visible in the companion animal segment. Investors should watch for further margin compression and market share loss to Dechra's Solovecin.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$77.05
T+0 close · Aug 6, 2026 · via day close
Latest settled
+3.47%
T+60 · $79.72
Vs SPY
+5.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $77.05entry
  2. T+1 · 3mo ago −6.09%α −6.70% · $72.36
  3. T+5 · 3mo ago −1.67%α −2.89% · $75.76
  4. T+20 · 3mo ago −0.99%α −1.58% · $76.29
  5. T+60 · 18d ago +3.47%α +5.14% · $79.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zoetis reported Q2 2026 adjusted EPS of $1.87, a 1% beat vs. $1.85 consensus, but revenue of $2.468B slightly missed the $2.51B estimate. The company slashed its full-year 2026 guidance, now expecting revenue of $9.12B-$9.32B (organic operational decline of 3%-1%) and adjusted EPS of $6.15-$6.25, down sharply from prior guidance of $6.85-$7.00. The U.S. companion animal business continued to deteriorate, with sales falling 11% due to pet owner price sensitivity and heightened competition, offsetting strength in livestock and international segments. This is a clear bearish signal as the core U.S. franchise is under structural pressure, leading to a significant guidance reduction that will likely drive the stock lower.

Key Financial Metrics

EPS
$1.87
est $1.85 · +1.1%
Revenue
$2.5B
est $2.5B · -1.7% · -0.2% YoY
Rating
miss
Guidance
$9.120B-$9.320B
lowered

Key Facts

  • Q2 2026 revenue flat at $2.468B vs $2.474B YoY; organic operational revenue declined 1%
  • Adjusted EPS of $1.87 beat consensus of $1.85 by 1%
  • U.S. segment revenue fell 7% to $1.266B; companion animal sales dropped 11%
  • Full-year 2026 revenue guidance slashed to $9.12B-$9.32B from $9.68B-$9.96B (organic operational growth of -3% to -1%)
  • Full-year 2026 adjusted EPS guidance cut to $6.15-$6.25 from $6.85-$7.00
  • Adjusted net income guidance for organic operational growth revised to -9% to -5% from +2% to +6%
  • Restructuring charges of $77M in Q2, primarily for employee termination costs under a cost and productivity program

Financial Impact

Full-year revenue guidance cut by ~$560M-$640M at midpoint; adjusted EPS guidance cut by ~$0.70 at midpoint

revenueepsguidance

Risk Factors

  • Continued deterioration in U.S. companion animal demand due to pet owner price sensitivity
  • Intensifying competition in key categories (dermatology, parasiticides) and generic erosion of Convenia/Cerenia
  • Execution risk on cost restructuring program; potential for further guidance cuts if trends worsen

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
54% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001555280-26-000038
Document: zts-20260806.htm0001555280-26-000038
Document: 0001555280-26-000038-index-headers.html0001555280-26-000038
Document: 0001555280-26-000038-index.html0001555280-26-000038
Document: 0001555280-26-000038.txt0001555280-26-000038
8-K Data (Synthetic)0001555280-26-000038

Track record

10 reports on ZTS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +38.10% at T+60 after the Feb 27, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $82.11 to $79.40 Now $84.39 −2.78% ▲ +3.30% +3.61% vs SPY
  2. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $79.52 to $79.96 Now $84.39 +6.13% ▲ +0.55% +0.22% vs SPY
  3. Oct 13, 20264w ago 8-K Neutral 2/10 Entry $74.30 to $75.29 Now $84.39 +13.58% ▲ +1.33% +2.41% vs SPY
  4. Oct 8, 20265w ago 8-K Neutral 2/10 Entry $74.81 to $75.65 Now $84.39 +12.81% ▲ +1.12% +1.18% vs SPY
  5. Aug 6, 202614w ago 8-K Bearish 7/10 Viewing Entry $77.05 to $72.36 Now $84.39 −9.53% ▲ +6.09% +6.70% vs SPY
  6. May 20, 202625w ago 8-K Neutral 2/10 Entry $79.98 to $81.17 Now $84.39 +5.52% ▲ +1.49% +1.04% vs SPY
  7. May 13, 202626w ago Insider Cluster Neutral 2/10 Entry $75.24 to $73.62 Now $84.39 +12.16% ▼ −2.15% −0.93% vs SPY
  8. May 7, 202627w ago 8-K Bearish 7/10 Entry $87.24 to $82.31 Now $84.39 +3.27% ▲ +5.65% +6.48% vs SPY
  9. Apr 8, 202631w ago DEFA14A Neutral 2/10 Entry $119.65 to $119.47 Now $84.39 −29.47% ▼ −0.15% −0.72% vs SPY
  10. Feb 27, 202637w ago Court Ruling Bearish 6/10 Entry $127.51 to $124.52 Now $84.39 +33.82% ▲ +2.35% +1.47% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (11h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026